For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major ...
Explore the role of depression drugs targeting the neurokinin-1 receptor and their potential impact on major depressive ...
10d
Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist
The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated ...
For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major ...
Dr. Hans Eriksson, Chief Medical Officer, presented clinical findings from the OLIVE Phase 2b trial, which evaluated BH-200 (nelivaptan) in 338 patients with Major Depressive Disorder (MDD), using a ...
Losartan may help stop the epileptic process in certain patients with hypertension. An observational study that analyzed medical records of 2.26 million patients with hypertension found a roughly 30% ...
We are very pleased to nominate AMX0318 as a development candidate and were highly impressed by Gubra’s proprietary and ...
Role of the RAAS in the Pathophysiology of Heart Failure ACE inhibitors have no effect on angiotensin II formed by alternate pathways. In contrast, ARBs would be expected to inhibit the biologic ...
Older patients with hypertension are often inadequately treated due to misconceptions regarding reasonable goal blood pressures or concerns about treatment side effects. Adequately treating ...
For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder. Early studies suggested promise, but enthusiasm faded after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback